Certain supplemental information not included in the press release

EX-99.2 3 dex992.htm CERTAIN SUPPLEMENTAL INFORMATION NOT INCLUDED IN THE PRESS RELEASE Certain supplemental information not included in the press release

Exhibit 99.2

MERCK & CO., INC.

OTHER FINANCIAL DISCLOSURES

FOURTH QUARTER

2008

EQUITY INCOME FROM AFFILIATES (millions of dollars)

4Q `08

4Q `07

YTD 2008

YTD 2007

MERCK / SCHERING-PLOUGH

378.1

537.7

1,536.3

1,830.8

ASTRAZENECA LP

266.8

211.8

598.4

820.1

Other⁽¹⁾

75.1

46.8

425.9

325.6

TOTAL

720.0

796.3

2,560.6

2,976.5

⁽¹⁾

Primarily reflects results for Merial Limited, Sanofi Pasteur-MSD and Johnson & JohnsonºMerck Consumer Pharmaceuticals.

JOINT VENTURE SALES DETAIL (millions of dollars)

All sales reported here are end-market JV sales, presented on a “NET” basis.

Merial

4Q `08

4Q `07

YTD 2008

YTD 2007

FRONTLINE, other fipronil

152.0

167.2

1,053.0

1,033.3

BIOLOGICALS

208.8

202.1

789.7

674.9

IVOMEC, HEARTGARD, other avermectins

96.8

111.7

511.8

478.4

Other Animal Health

67.4

70.2

288.2

262.2

TOTAL MERIAL SALES

525.0

551.2

2,642.7

2,448.8

Sanofi Pasteur-MSD

4Q `08

4Q `07

YTD 2008

YTD 2007

GARDASIL

171.2

231.0

865.3

476.0

VIRAL VACCINES

24.4

21.8

105.1

86.8

HEPATITIS VACCINES

15.9

19.0

72.6

72.9

Other Vaccines

265.1

267.3

841.8

802.3

TOTAL SANOFI PASTEUR-MSD SALES

476.6

539.1

1,884.8

1,438.0

Merck / Schering-Plough Collaboration

4Q `08

4Q `07

YTD 2008

YTD 2007

VYTORIN

549.5

775.9

2,360.0

2,779.1

ZETIA

524.7

678.6

2,201.1

2,407.1

TOTAL MERCK / SCHERING-PLOUGH SALES

1,074.2

1,454.5

4,561.1

5,186.2

OTHER (INCOME) EXPENSE, NET (millions of dollars)

4Q `08

4Q `07

YTD 2008

YTD 2007

INTEREST INCOME

(147.2

)

(200.2

)

(631.4

)

(741.1

)

INTEREST EXPENSE

56.7

87.1

251.3

384.3

EXCHANGE LOSSES (GAINS)

73.8

(14.5

)

147.4

(54.3

)

MINORITY INTERESTS

30.0

29.4

123.9

121.4

Other, net ⁽¹⁾

(10.1

)

665.6

(2,085.4

)

335.9

TOTAL

3.2

567.4

(2,194.2

)

46.2

⁽¹⁾

Other, net for full year 2008 primarily reflects a gain of $2.2 billion related to a distribution from AstraZeneca LP. Other, net for the fourth quarter and full year 2007 reflects a civil governmental investigations charge of $671.1 million.

MERCK & CO., INC.

OTHER FINANCIAL DISCLOSURES

FOURTH QUARTER

2008

NET PRODUCT SALES DETAIL (millions of dollars)


	4Q `08 vs. 4Q `07
PRODUCT	TOTAL % CHG		TOTAL $	U.S. % CHG		U.S. $	Foreign % CHG		Foreign $
COZAAR / HYZAAR	-1	%	881	-3	%	319	—		562
FOSAMAX	-60	%	318	-85	%	77	-12	%	241
SINGULAIR	-3	%	1,122	-11	%	709	15	%	413
Vaccines:
GARDASIL	-16	%	286	-19	%	216	-2	%	69
ROTATEQ	9	%	162	4		148	*		14
ZOSTAVAX	89	%	162	89	%	162	N/A		—
OTHER VIRAL VACCINES ⁽¹⁾	-10	%	295	-11	%	278	3	%	17
HEPATITIS VACCINES ⁽²⁾	-33	%	40	-32	%	33	-38	%	7
OTHER VACCINES ⁽³⁾	5	%	132	8	%	97	-2	%	35
Other Reported Products:
ARCOXIA	-1	%	83	N/A		—	-1	%	83
CANCIDAS	4	%	139	4	%	21	4	%	118
COSOPT / TRUSOPT	-27	%	154	-62	%	37	1	%	117
CRIXIVAN / STOCRIN	-35	%	52	-34	%	3	-35	%	49
EMEND	16	%	71	23	%	47	6	%	24
INVANZ	29	%	68	35	%	38	21	%	30
ISENTRESS	*		130	*		71	*		59
JANUVIA	64	%	413	41	%	323	*		89
JANUMET	*		120	*		99	*		20
MAXALT	12	%	141	15	%	97	7	%	44
PRIMAXIN	-13	%	169	-24	%	39	-10	%	130
PROPECIA	-4	%	108	-5	%	37	-3	%	71
PROSCAR	-14	%	72	-46	%	2	-12	%	69
TIMOPTIC / TIMOPTIC XE	-3	%	31	-9	%	2	-3	%	29
VASOTEC / VASERETIC	-32	%	85	N/A		—	-32	%	85
ZOCOR	-34	%	147	-80	%	11	-19	%	136
ZOLINZA	64	%	5	62	%	4	*		—

*	100% or over

N/A -

Not Applicable

⁽¹⁾-	Includes ProQuad, M-M-R II and Varivax.

⁽²⁾ -

Includes Recombivax and Vaqta

⁽³⁾ -

Includes Pneumovax, Comvax and Pedvaxhib

TOTAL SALES: VOLUME, PRICE, EXCHANGE


	4Q `08		% CHG		VOL	PX	FX
TOTAL PHARMACEUTICAL SALES	$	6,032	-3	%	-4	1	-1

U.S. ($ MM)		3,396	-9	%	-12	4	N/A
Foreign ($ MM)		2,636	5	%	10	-3	-2

MERCK & CO., INC.

OTHER FINANCIAL DISCLOSURES

DECEMBER YEAR-TO-DATE

2008

NET PRODUCT SALES DETAIL (millions of dollars)


	DECEMBER YTD `08 vs. DECEMBER YTD `07
PRODUCT	TOTAL % CHG		TOTAL $	U.S. % CHG		U.S. $	Foreign % CHG		Foreign $
COZAAR / HYZAAR	6	%	3,558	1	%	1,247	9	%	2,311
FOSAMAX	-49	%	1,553	-75	%	498	-1	%	1,054
SINGULAIR	2	%	4,337	-6	%	2,825	19	%	1,511
Vaccines:
GARDASIL	-5	%	1,403	-13	%	1,041	26	%	362
ROTATEQ	27	%	665	24	%	618	83	%	46
ZOSTAVAX	32	%	312	32	%	312	N/A		—
OTHER VIRAL VACCINES ⁽¹⁾	-6	%	1,268	-8	%	1,175	38	%	94
HEPATITIS VACCINES ⁽²⁾	-47	%	148	-52	%	112	-21	%	36
OTHER VACCINES ⁽³⁾	-13	%	355	-32	%	206	38	%	149
Other Reported Products:
ARCOXIA	15	%	377	N/A		—	15	%	377
CANCIDAS	11	%	596	-21	%	100	21	%	496
COSOPT / TRUSOPT	-1	%	781	-17	%	291	12	%	491
CRIXIVAN / STOCRIN	-11	%	275	-36	%	13	-10	%	262
EMEND	29	%	264	24	%	172	41	%	92
INVANZ	39	%	265	32	%	138	48	%	127
ISENTRESS	*		361	*		202	*		159
JANUVIA	*		1,397	79	%	1,110	*		287
JANUMET	*		351	*		308	*		43
MAXALT	13	%	529	13	%	354	14	%	175
PRIMAXIN	—		760	-22	%	163	8	%	598
PROPECIA	6	%	429	-1	%	151	10	%	278
PROSCAR	-21	%	324	-79	%	12	-12	%	311
TIMOPTIC / TIMOPTIC XE	2	%	122	-10	%	7	2	%	115
VASOTEC / VASERETIC	-28	%	357	N/A		—	-28	%	357
ZOCOR	-25	%	660	-59	%	75	-16	%	585
ZOLINZA	40	%	15	34	%	14	*		1

*	100% or over

N/A	- Not Applicable

⁽¹⁾	- Includes ProQuad, M-M-R II and Varivax.

⁽²⁾	- Includes Recombivax and Vaqta

⁽³⁾	- Includes Pneumovax, Comvax and Pedvaxhib

TOTAL SALES: VOLUME, PRICE, EXCHANGE


	FY `08		% CHG		VOL	PX	FX
TOTAL PHARMACEUTICAL SALES	$	23,850	-1	%	-4	—	3

U.S. ($ MM)		13,370	-9	%	-11	2	N/A
Foreign ($ MM)		10,480	10	%	7	-4	7